Trial Profile
A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms IMvigor130
- Sponsors Chugai Pharmaceutical; Roche
- 28 Mar 2024 This study has been Completed in Portugal, According to European Clinical Trials Database record.
- 08 Mar 2024 This study has been Completed in Netherlands, According to European Clinical Trials Database record.
- 31 Jan 2024 Planned End Date changed from 31 Dec 2023 to 12 Feb 2024.